COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00403910
Recruitment Status : Completed
First Posted : November 27, 2006
Last Update Posted : April 17, 2009
Information provided by:
Heart Care Foundation

Brief Summary:
The RALES study has shown that spironolactone reduces the risk of morbidity and mortality both from progressive heart failure and sudden death, in patients with NYHA III or IV heart failure. This favourable effect was clearly independent from a diuretic effect. Antialdosterone drugs may be effective because they opposes the effects of aldosterone on sodium retention, loss of magnesium and potassium, sympathetic activation, baroreceptor function and vascular compliance. Antialdosterone treatment may also antagonize the effect of aldosterone in promoting cardiac fibrosis. In a RALES substudy baseline serum PIIINP, a marker of cardiac fibrosis synthesis showed an independent negative correlation with survival and CHF hospitalizations in the placebo group. Therefore it seems interesting to evaluate the effect of an Aldosterone receptor blocker on progression of left ventricular dysfunction in patients with mild heart failure assuming standard therapy.

Condition or disease Intervention/treatment Phase
Heart Failure Drug: Canrenone Phase 3

Detailed Description:
The protocol is sponsored by and independent organization and partially supported by Therabel

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Diagnostic
Official Title: Phase 3 Study Of Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure
Study Start Date : September 2002
Study Completion Date : July 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
Drug Information available for: Aldosterone

Primary Outcome Measures :
  1. Changes in echocardiographic left ventricular diastolic volume

Secondary Outcome Measures :
  1. Changes in left ventricular systolic volume
  2. Changes in ejection fraction
  3. Changes in NYHA class
  4. cardiac mortality
  5. hospitalization for cardiac causes
  6. combination of cardiac mortality hospitalizations for cardiac causes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Established diagnosis of congestive heart failure in NYHA class II
  • Left ventricular ejection fraction <= 45% measured within 6 months from enrolment
  • Stable standard heart failure therapy (if patients are on beta blocker drugs, treatment must have been started at least three months before enrolment)
  • Informed consent (obtained prior of any study procedures)

Exclusion Criteria:

  • Age <18 and >80
  • Serum creatinine level > 2.5 mg per deciliter
  • Serum potassium level > 5.0 mmol per liter
  • Valvular heart disease amenable to surgical treatment
  • Congenital heart disease
  • Unstable angina and/or acute myocardial infarction and/or coronary revascularization procedure within three months before enrolment
  • Intravenous therapy with inotropic drugs within three months before enrolment
  • History of resuscitated ventricular fibrillation or tachycardia, unless these occurred within 24 hours of an acute myocardial infarction or the subject has an implanted an automatic cardioverter defibrillator
  • Chronic active hepatitis or cirrhosis
  • Malignant neoplasm or any life threatening non cardiac disease
  • History of hypersensitivity to study drug
  • Pregnancy or lactating or childbearing age women who are not protected by an accepted method of contraception
  • History of drug or alcohol abuse
  • Legal incapacity and/or other circumstances rending the patient unable to understand the nature, scope and possible consequences of the study.
  • Evidence of uncooperative attitude
  • Any condition other than heart failure that does not permit an optimal participation to the trial
  • Participation to other RCTs during the last 3 months
  • Treatment with: Lithium salts, Potassium sparing diuretics, oral positive inotropic drugs or any investigational drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00403910

Show Show 45 study locations
Sponsors and Collaborators
Heart Care Foundation
Layout table for investigator information
Study Chair: Alessandro Boccanelli, MD Ospedale San Giovanni di Roma
Additional Information:
Publications of Results:
Other Publications:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00403910    
Other Study ID Numbers: 17
First Posted: November 27, 2006    Key Record Dates
Last Update Posted: April 17, 2009
Last Verified: April 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Natriuretic Agents